← 返回前沿论文

slan+单核细胞通过胞噬作用杀死被治疗性抗体包被的癌细胞

英文原题:slan+ Monocytes Kill Cancer Cells Coated in Therapeutic Antibody by Trogoptosis.

PubMed 2023/11/01(内容时间) Cancer Immunol Res Q1 · IF 7.9(JCR 2025)

研究概要

我们的观察为slan+单核细胞在抗体依赖性肿瘤细胞靶向中发挥的细胞毒性机制提供了新的见解,并增进了我们对如何扩展癌症治疗武器库的认识。

中文摘要

6-Sulfo LacNAc(slan)阳性的单核细胞是人类非经典CD14dimCD16+单核细胞的主要亚群。我们已证明,slan+细胞可浸润淋巴瘤,并由抗CD20治疗性抗体利妥昔单抗介导对肿瘤性B细胞的抗体依赖性细胞毒性(ADCC)。在此,通过进行阻断实验和流式细胞术分析,以及共聚焦显微镜和活细胞成像实验,我们将这些发现扩展至其他人源化抗体,并阐明了潜在的效应机制。具体而言,我们显示,在与包被抗CD20或抗CD38的靶细胞共培养后,slan+单核细胞介导trogocytosis,这是一种依赖细胞间接触、由抗体介导的过程,可触发对靶细胞膜的主动、机械性破坏。slan+单核细胞介导的trogocytosis导致一种坏死型靶细胞死亡,称为trogoptosis,其一经启动,部分由内源性TNFα维持。我们还发现,与自然杀伤(NK)细胞不同,slan+单核细胞对所有分析过的抗CD47类型均介导直接的ADCC,且这与其IgG同种型无关。后一发现揭示了slan+单核细胞在临床实践中介导抗CD47治疗效果方面可能具有的相关贡献,当NK细胞耗竭或数量不足时,这一点可能尤为重要。总体而言,我们的观察为slan+单核细胞在抗体依赖性肿瘤细胞靶向中发挥的细胞毒性机制提供了新的认识,并推进了我们对如何扩展癌症治疗手段的认识。

展开英文摘要原文

Monocytes positive for 6-Sulfo LacNAc (slan) are a major subset of nonclassical CD14dimCD16+ monocytes in humans. We have shown that slan+ cells infiltrate lymphomas and elicit an antibody-dependent cellular cytotoxicity (ADCC) of neoplastic B cells mediated by the anti-CD20 therapeutic rituximab. Herein, by performing blocking experiments and flow cytometry analyses, as well as confocal microscopy and live-cell imaging assays, we extended the findings to other humanized antibodies and deciphered the underlying effector mechanism(s). Specifically, we show that, after coculture with target cells coated with anti-CD20 or anti-CD38, slan+ monocytes mediate trogocytosis, a cell-cell contact dependent, antibody-mediated process that triggers an active, mechanic disruption of target cell membranes. Trogocytosis by slan+ monocytes leads to a necrotic type of target cell death known as trogoptosis, which, once initiated, was partially sustained by endogenous TNFα. We also found that slan+ monocytes, unlike natural killer (NK) cells, mediate a direct ADCC with all types of anti-CD47 analyzed, and this was independent of their IgG isotype. The latter findings unveil a potentially relevant contribution by slan+ monocytes in mediating the therapeutic efficacy of anti-CD47 in clinical practice, which could be particularly important when NK cells are exhausted or deficient in number. Overall, our observations shed new light on the cytotoxic mechanisms exerted by slan+ monocytes in antibody-dependent tumor cell targeting and advance our knowledge on how to expand our therapeutic arsenal for cancer therapy.

论文信息

作者
Finotti G、Pietronigro E、Balanzin C、Lonardi S、Constantin G、Chao MP、Tecchio C、Vermi W
单位
Section of General Pathology, Department of Medicine, University of Verona, Verona, Italy.Italy
文献类型
非美国政府资助研究
期刊
Cancer immunology research2023 Nov 1
原文标识
PubMed 37695535 · DOI 10.1158/2326-6066.CIR-23-0239